Interleukin-33 (IL-33) is a cytokine with pleiotropic functions in various diseases; however, its role in the antitumor immune response is still unclear. We found the expression of IL-33/ST2 in nonsmall cell lung tumor microenvironment. Furthermore, we found that IL-33 promoted effector functions of CD8+ T cells that play a critical role in antitumor immune response. In addition, we found that IL-33 enhanced tumor vaccine effector functions in mice. Altogether, these findings suggest that IL-33, through facilitates CD8+ T cells in microenvironment to provide a profound effect in antitumor immunotherapy.
Get full access to this article
View all access options for this article.
References
1.
BonnelykkeK, SleimanP, NielsenK, Kreiner-MollerE, MercaderJM, BelgraveD, den DekkerHT, HusbyA, SevelstedA, Faura-TellezG, MortensenLJ, PaternosterL, FlaatenR, MolgaardA, SmartDE, ThomsenPF, RasmussenMA, Bonas-GuarchS, HolstC, NohrEA, YadavR, MarchME, BlicherT, LackiePM, JaddoeVW, SimpsonA, HollowayJW, DuijtsL, CustovicA, DaviesDE, TorrentsD, GuptaR, HollegaardMV, HougaardDM, HakonarsonH, BisgaardH. 2014. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. Nat Genet, 46(1):51–55.
CayrolC, GirardJP. 2009. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A, 106(22):9021–9026.
4.
ChackerianAA, OldhamER, MurphyEE, SchmitzJ, PflanzS, KasteleinRA. 2007. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol, 179(4):2551–2555.
5.
GalonJ, CostesA, Sanchez-CaboF, KirilovskyA, MlecnikB, Lagorce-PagesC, TosoliniM, CamusM, BergerA, WindP, ZinzindohoueF, BrunevalP, CugnencPH, TrajanoskiZ, FridmanWH, PagesF. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 313(5795):1960–1964.
6.
GassaA, JianF, KalkavanH, DuhanV, HonkeN, ShaabaniN, FriedrichSK, DolffS, WahlersT, KribbenA, HardtC, LangPA, WitzkeO, LangKS. 2016. IL-10 Induces T cell exhaustion during transplantation of virus infected hearts. Cell Physiol Biochem, 38(3):1171–1181.
7.
HolderriedTA, LangPA, KimHJ, CantorH. 2013. Genetic disruption of CD8+ Treg activity enhances the immune response to viral infection. Proc Natl Acad Sci U S A, 110(52):21089–21094.
8.
JovanovicIP, PejnovicNN, RadosavljevicGD, PanticJM, MilovanovicMZ, ArsenijevicNN, LukicML. 2014. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer, 134(7):1669–1682.
9.
LiuGY, JiaQY, LiZJ, LiYG, ZhangMM, LiuMY, WangXL, LiY. 2014. Adenovirus-mediated CCL20/IL-15 gene transfer enhances antitumor immunity in mice. Immunobiology, 219(6):475–481.
10.
LuthiAU, CullenSP, McNeelaEA, DuriezPJ, AfoninaIS, SheridanC, BrumattiG, TaylorRC, KersseK, VandenabeeleP, LavelleEC, MartinSJ. 2009. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity, 31(1):84–98.
11.
MoussionC, OrtegaN, GirardJP. 2008. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?. PLoS One, 3(10):e3331.
12.
PicheryM, MireyE, MercierP, LefrancaisE, DujardinA, OrtegaN, GirardJP. 2012. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol, 188(7):3488–3495.
13.
RossleM, CathomasG, BonapaceL, SachsM, DehlerS, StorzM, HuberG, MochH, JuntT, MertzKD. 2016. Interleukin-33 expression indicates a favorable prognosis in malignant salivary gland tumors. Int J Surg Pathol, 24(5):394–400.
14.
SchmitzJ, OwyangA, OldhamE, SongY, MurphyE, McClanahanTK, ZurawskiG, MoshrefiM, QinJ, LiX, GormanDM, BazanJF, KasteleinRA. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 23(5):479–490.
15.
SchreiberRD, OldLJ, SmythMJ. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 331(6024):1565–1570.
16.
SmithgallMD, ComeauMR, YoonBR, KaufmanD, ArmitageR, SmithDE. 2008. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol, 20(8):1019–1030.
17.
SuZ, LinJ, LuF, ZhangX, ZhangL, GandhiNB, de PaivaCS, PflugfelderSC, LiDQ. 2013. Potential autocrine regulation of interleukin-33/ST2 signaling of dendritic cells in allergic inflammation. Mucosal Immunol, 6(5):921–930.
YangQ, LiG, ZhuY, LiuL, ChenE, TurnquistH, ZhangX, FinnOJ, ChenX, LuB. 2011. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol, 41(11):3351–3360.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
